Drug Profile
Tibulizumab - Eli Lilly and Company
Alternative Names: Anti-BAFF IL-17A monoclonal antibody - Eli Lilly and Company; BAFF/IL-17A-Eli-Lilly and Company; LY-3090106; ZB-106Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antirheumatics; Bispecific antibodies; Small molecules
- Mechanism of Action B cell activating factor inhibitors; Interleukin-17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Rheumatoid arthritis; Sjogren's syndrome